Pilot study finds optimized selumetinib dosing improves safety in pediatric neurofibromatosis type 1, suggesting tailored approaches are beneficial.
Higher selumetinib exposure appears to be associated with treatment-related adverse effects in pediatric NF1 patients. These findings support the potential role of TDM in optimizing selumetinib dosing and provide a preliminary therapeutic AUC range for individualized treatment strategies. Larger multicenter studies are needed to validate these results and refine exposure-guided dosing approaches.
No takes yet. Share an insight, caveat, or question.
Kovács et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: